MaaT Pharma Presents Promising Detailed Results from Completed Phase 1b Trial with MaaT033 at the 64th ASH Annual Meeting Detailed…
Categorie
2022
MaaT Pharma Presents Compelling Consolidated MaaT013 Clinical Data at the 64th ASH Annual Meeting Oral presentation at 64th American Society…
December 10, 2022
MaaT Pharma To Webcast Investor Meeting in Conjunction with ASH 2022 Conference MaaT Pharma will host a webcast conference for…
November 29, 2022
MaaT Pharma Reports Cash and Revenues for Third Quarter 2022 As of September 30, 2022, cash and cash equivalents were…
November 8, 2022
MaaT Pharma Announces Participation in Scientific and Investor Conferences in November Lyon, France, November 7th, 2022, 6:00pm CET – MaaT Pharma…
November 7, 2022
MaaT Pharma Announces Oral and Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting Oral presentation will…
November 3, 2022
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of the General…
October 7, 2022
MaaT Pharma Appoints Nathalie Corvaïa as Chief Scientific Officer and Strengthens its R&D activities in Immuno-Oncology Lyon, France, October 4th,…
October 4, 2022
MaaT Pharma Publishes its Half Year Results and Provides a Business Overview For the first half of 2022 turnover was…
September 29, 2022
MaaT Pharma Announces Participation in Three Upcoming Investor Conferences in September Lyon, France, September 8th, 2022 – 6:00 pm CET…
September 8, 2022
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
Ressources
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.